Durability of Antiretroviral Suppression and the Real World Clinical Profile of the Novel 2‐Drug Regimen Juluca, a Onepill‐Regimen Consisting of Dolutegravir and Rilpivirine, in Routine Clinical Care in Germany

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 05 Sep 2019

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dolutegravir/rilpivirine (Primary)
Indications HIV-1 infections
Focus Therapeutic Use
Acronyms JUNGLE
Sponsors ViiV Healthcare

Most Recent Events

29 Aug 2019 Planned End Date changed from 29 Jul 2022 to 1 Dec 2021.
29 Aug 2019 Planned primary completion date changed from 29 Jul 2022 to 1 Dec 2021.
29 Aug 2019 Status changed from recruiting to active, no longer recruiting.

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Welcome to AdisInsight